贝伐珠单抗联合紫杉醇对比安慰剂联合紫杉醇一线治疗HER2阴性转移性乳腺癌(MERiDiAN):一项前瞻性生物标志物评估的双盲安慰剂对照随机III期试验
MERiDiAN研究前瞻性评估血浆血管内皮生长因子A(pVEGF-A)作为贝伐珠单抗治疗转移性乳腺癌的预测生物标志物,共随机481例患者(安慰剂-紫杉醇组242例,贝伐珠单抗-紫杉醇组239例)。意向治疗人群分层PFS风险比为0.68(99%CI 0.51-0.91;p=0.0007),pVEGF-A高亚组分层的PFS风险比为0.64(96%CI 0.47-0.88;p=0.0038),但PFS与VEGF-A的交互作用p值为0.4619。结论提示贝伐珠单抗显著改善PFS,但不支持用基线pVEGF-A筛选获益患者。
要点
- 意向治疗人群贝伐珠单抗组中位PFS 11.0个月 vs 安慰剂组8.8个月,分层HR 0.68。
- pVEGF-A高亚组分层HR 0.64,但PFS与VEGF-A交互作用p值为0.4619。
- 贝伐珠单抗组出血、中性粒细胞减少、高血压发生率均高于安慰剂组。
核心结论
- 贝伐珠单抗联合紫杉醇较安慰剂联合紫杉醇显著改善PFS,结果与既往转移性乳腺癌一线安慰剂对照试验一致。
- 结果不支持使用基线pVEGF-A来识别最可能从贝伐珠单抗获益的患者。
研究设计与样本
- 双盲、安慰剂对照、随机III期试验,纳入既往未接受化疗的HER2阴性转移性乳腺癌患者。
- 共随机481例患者(安慰剂-紫杉醇组242例,贝伐珠单抗-紫杉醇组239例),其中471例接受了研究治疗。
- 随机前检测pVEGF-A,分层因素包括基线pVEGF-A、既往辅助化疗、激素受体状态和地理区域。
- 治疗方案为紫杉醇90 mg/m2第1、8、15天联合安慰剂或贝伐珠单抗10 mg/kg第1、15天,每4周重复,直至疾病进展、不可接受毒性或撤回知情同意。
- 共同主要终点为意向治疗人群和pVEGF-A高人群中研究者评估的PFS。
主要发现
- 意向治疗人群分层PFS风险比0.68(99%CI 0.51-0.91;log-rank p=0.0007),中位PFS安慰剂-紫杉醇组8.8个月 vs 贝伐珠单抗-紫杉醇组11.0个月。
- pVEGF-A高亚组分层PFS风险比0.64(96%CI 0.47-0.88;log-rank p=0.0038)。
- PFS与VEGF-A交互作用p值(次要终点)为0.4619。
- 贝伐珠单抗组出血发生率45% vs 安慰剂组27%(所有级别);中性粒细胞减少所有级别39% vs 29%,≥3级25% vs 13%;高血压所有级别31% vs 13%,≥3级11% vs 4%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: MERiDiAN evaluated plasma vascular endothelial growth factor-A (pVEGF-A) prospectively as a predictive biomarker for bevacizumab efficacy in metastatic breast cancer (mBC). METHODS: In this double-blind placebo-controlled randomised phase III trial, eligible patients had HER2-negative mBC previously untreated with chemotherapy. pVEGF-A was measured before randomisation to paclitaxel 90 mg/m2 on days 1, 8 and 15 with either placebo or bevacizumab 10 mg/kg on days 1 and 15, repeated every 4 weeks until disease progression, unacceptable toxicity or consent withdrawal. Stratification factors were baseline pVEGF-A, prior adjuvant chemotherapy, hormone receptor status and geographic region. Co-primary end-points were investigator-assessed progression-free survival (PFS) in the intent-to-treat and pVEGF-Ahigh populations. RESULTS: Of 481 patients randomised (242 placebo-paclitaxel; 239 bevacizumab-paclitaxel), 471 received study treatment. The stratified PFS hazard ratio was 0.68 (99% confidence interval, 0.51-0.91; log-rank p = 0.0007) in the intent-to-treat population (median 8.8 months with placebo-paclitaxel versus 11.0 months with bevacizumab-paclitaxel) and 0.64 (96% confidence interval, 0.47-0.88; log-rank p = 0.0038) in the pVEGF-Ahigh subgroup. The PFS treatment-by-VEGF-A interaction p value (secondary end-point) was 0.4619. Bevacizumab was associated with increased incidences of bleeding (all grades: 45% versus 27% with placebo), neutropenia (all grades: 39% versus 29%; grade ≥3: 25% versus 13%) and hypertension (all grades: 31% versus 13%; grade ≥3: 11% versus 4%). CONCLUSION: The significant PFS improvement with bevacizumab is consistent with previous placebo-controlled first-line trials in mBC. Results do not support using baseline pVEGF-A to identify patients benefitting most from bevacizumab. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov NCT01663727.
引用
- Miles D, Cameron D, Bondarenko I, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer. 2016. PMID: 27817944. doi:10.1016/j.ejca.2016.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。